liu.seSearch for publications in DiVA
Change search
ReferencesLink to record
Permanent link

Direct link
DNA-VLP prime-boost intra-nasal immunization induces cellular and humoral anti-HIV-1 systemic and mucosal immunity with cross-clade neutralizing activity
Viral Oncogenesis and Immunotherapies & AIDS Reference Center, Italy.
Linköping University, Department of Molecular and Clinical Medicine, Molecular Virology. Linköping University, Faculty of Health Sciences.
Viral Oncogenesis and Immunotherapies & AIDS Reference Center, Italy.
Eurocine Vaccines AB, Sweden.
Show others and affiliations
2007 (English)In: Vaccine, ISSN 0264-410X, E-ISSN 1873-2518, Vol. 25, no 32, 5968-5977 p.Article in journal (Refereed) Published
Abstract [en]

The immune response to HIV-1 virus-like particles (VLPs), presenting a clade A Ugandan gp120, has been evaluated in a mouse model by intra-nasal (i.n.) administration by a VLP + VLP homologous or a DNA + VLP heterologous prime-boost immunization protocol, including a HIV-1 DNA gp160/rev plasmid. Furthermore, the effect of the Eurocine lipid-based mucosal L3 adjuvant on the VLP immunogenicity has been assessed as well. The designed heterologous protocol is able to increase the env-specific humoral and cellular immune response, compared to the homologous protocol, which is to some extent increased by the administration of L3-adjuvanted VLP boosting dose. The anti-gag response is statistically increased in both homologous and heterologous protocols, particularly when the VLP boosting dose is adjuvanted. Immune sera from immunized animals exhibit >50% ex vivo neutralizing activity against heterologous A and B-clade viral isolates. An envelope B-cell epitope mapping shows an enhanced response against V3 epitopes all across the C2-V5 region in the heterologous prime-boost immunization strategy. The induction of humoral immunity at mucosal sites, which represents the main port of entry for the HIV-1 infection, is extremely relevant. In this framework, the DNA-VLP heterologous prime-boost protocol appears a promising preventive vaccine approach which can significantly benefit from specific mucosal adjuvants, as the Eurocine L3. © 2007 Elsevier Ltd. All rights reserved.

Place, publisher, year, edition, pages
2007. Vol. 25, no 32, 5968-5977 p.
National Category
Medical and Health Sciences
URN: urn:nbn:se:liu:diva-38564DOI: 10.1016/j.vaccine.2007.05.052Local ID: 44769OAI: diva2:259413
Available from: 2009-10-10 Created: 2009-10-10 Last updated: 2012-08-31

Open Access in DiVA

fulltext(361 kB)277 downloads
File information
File name FULLTEXT01.pdfFile size 361 kBChecksum SHA-512
Type fulltextMimetype application/pdf

Other links

Publisher's full text

Search in DiVA

By author/editor
Devito, CHinkula, Jorma
By organisation
Molecular VirologyFaculty of Health Sciences
In the same journal
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
Total: 277 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 58 hits
ReferencesLink to record
Permanent link

Direct link